Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma.
Eleven patients with metastatic osteogenic sarcoma were treated with cyclophosphamide, adriamycin, and, in some cases, high-dose methotrexate. In the event of metastatic progression, the dose of cyclophosphamide was escalated by increasing the number of consecutive daily infusions (dose, 45 mg/kg/day). The results indicate that metastatic osteogenic sarcoma is marginally responsive to adriamycin and cyclophosphamide but rarely responsive to high-dose methotrexate as administered in this trial. The response of metastatic lesions was not improved by escalating the dose of cyclophosphamide.
D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate